Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASTRO 2022 | The impact of KRAS mutation and PD-1 status on outcomes of SBRT for NSCLC

Kevin Stephans • 18 Oct 2022
ASTRO 2022
Lung Cancer Non-Small Cell Lung Cancer

Kevin Stephans, MD, Cleveland Clinic, Cleveland, OH, discusses the impact of KRAS mutation and PD-1 status on outcomes of stereotactic body radiation therapy (SBRT) in non-small cell lung cancer (NSCLC). This interview took place at the American Society for Radiation Oncology (ASTRO) 2022 Congress in San Antonio, Tx.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Kevin Stephans

2:32
The use of single-fraction SBRT versus multi-fraction SBRT for lung cancers and metastases
Kevin Stephans • 18 Oct 2022
1:39
The impact of time-to-treatment on SBRT outcomes
Kevin Stephans • 18 Oct 2022
3:14
The impact of stereotactic body radiation therapy on outcomes in NSCLC
Kevin Stephans • 18 Oct 2022

Related Videos

2:45
Assessing operability in NSCLC: challenges and considerations
Mariana Brandao • 18 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals